CEN Biotech, Inc.
CENBF
$0.0001
$0.000.00%
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | 404.56% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 404.56% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 404.56% | -- | -- | -- | -- |
| SG&A Expenses | -85.06% | -83.14% | 809.57% | 726.80% | 611.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -85.06% | -83.14% | 809.57% | 726.80% | 611.12% |
| Operating Income | 92.62% | 91.72% | -761.73% | -698.41% | -600.29% |
| Income Before Tax | -235.28% | -413.79% | -224.45% | -232.92% | 137.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -233.69% | -410.46% | -224.20% | -232.66% | 137.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -233.69% | -410.46% | -224.20% | -232.66% | 137.62% |
| EBIT | 92.62% | 91.72% | -761.73% | -698.41% | -600.29% |
| EBITDA | 94.92% | 93.66% | -966.92% | -868.57% | -726.70% |
| EPS Basic | -120.55% | -129.76% | -181.64% | -188.90% | 222.24% |
| Normalized Basic EPS | 94.20% | 93.00% | -91.56% | -78.08% | -131.86% |
| EPS Diluted | -194.12% | 8.98% | -281.59% | -310.30% | 90.95% |
| Normalized Diluted EPS | 93.78% | 92.54% | -126.05% | -106.21% | -116.38% |
| Average Basic Shares Outstanding | 54.87% | 66.52% | 67.92% | 55.25% | 31.90% |
| Average Diluted Shares Outstanding | 34.33% | 41.39% | 40.00% | 29.32% | 52.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
